scholarly journals Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer

Cancer ◽  
2016 ◽  
Vol 122 (15) ◽  
pp. 2341-2349 ◽  
Author(s):  
Aaron D. Falchook ◽  
Ramsankar Basak ◽  
Jahan J. Mohiuddin ◽  
Ronald C. Chen
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation ◽  
Intermediate Risk ◽  
Risk Prostate Cancer

Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity

Brachytherapy ◽  
2015 ◽  
Vol 14 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Yasuhiro Yamada ◽  
Koji Masui ◽  
Tsuyoshi Iwata ◽  
Yasuyuki Naitoh ◽  
Kei Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation ◽  
Prostate Brachytherapy ◽  
Intermediate Risk ◽  
Short Term ◽  
Japanese Men ◽  
Risk Prostate Cancer

Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 176-176
Author(s):  
Shelly Bian ◽  
Deborah A. Kuban ◽  
Lawrence B. Levy ◽  
Jeong Hoon Oh ◽  
Katherine Castle ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Androgen Deprivation Therapy ◽  
Recursive Partitioning ◽  
Androgen Deprivation ◽  
Intermediate Risk ◽  
Short Term ◽  
Free Survival ◽  
Risk Prostate Cancer ◽  
Severe Comorbidity

176 Background: Independently, dose-escalated external beam radiation therapy (DE-EBRT) and short-term androgen deprivation therapy (ADT) improve outcomes for men with intermediate-risk prostate cancer; however, the incremental benefit of adding short-term ADT to DE-EBRT is uncertain. The aim of this study was to determine the effect of adding ADT to DE-EBRT and to identify men most likely to benefit from ADT. Methods: We reviewed the medical records of 636 men treated for intermediate-risk prostate cancer with DE-EBRT (>75 Gy) from 1995 to 2009. The adult comorbidity evaluation-27 index categorized severity of comorbidity. Recursive partitioning analysis defined unfavorable disease. Kaplan-Meier and log-rank tests compared failure-free survival (FFS) with and without ADT. Results: Median age was 70 years (interquartile range [IQR] 65–74). Overall, 45% received DE-EBRT alone and 55% DE-EBRT with ADT (median 6 months, IQR 6-8). Median follow up was 4.3 years. On Cox-proportional hazard regression analysis that adjusted for differences in comorbidities and tumor characteristics, administration of ADT improved FFS (adjusted hazard ratio 0.36, 95% confidence interval 0.18–0.72; p=0.004). Recursive partitioning analysis of men without ADT classified Gleason 4+3=7 or ≥ 50% positive cores as unfavorable disease (5-year FFS 96.3% favorable vs. 81.6% unfavorable; p<0.001). The addition of ADT to DE-EBRT improved 5-year FFS for men with unfavorable disease (n=334; 81.6% vs. 92.9%; p=0.009) but did not improve FFS for men with favorable disease (n=302; 96.3% vs. 97.4%; p=0.874). When stratified by comorbidity, ADT improved FFS for men with unfavorable disease and no or mild comorbidity (p=0.006) but did not improve FFS for men with unfavorable disease and moderate to severe comorbidity (p=0.380). Conclusions: The addition of ADT to DE-EBRT improves FFS for men with unfavorable intermediate-risk prostate cancer (Gleason 4+3=7 or ≥ 50% positive cores) especially those with no or minimal comorbidity. Men with favorable intermediate-risk disease or with moderate to severe comorbidity may not benefit from the addition of ADT to DE-EBRT.

A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5019-5019 ◽  
Author(s):  
Abdenour Nabid ◽  
Nathalie Carrier ◽  
Eric Vigneault ◽  
Luis Souhami ◽  
Céline Lemaire ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Phase Iii ◽  
Intermediate Risk ◽  
Short Term ◽  
Phase Iii Trial ◽  
Risk Prostate Cancer

Androgen deprivation in combination with radiotherapy in intermediate-risk prostate cancer

2013 ◽  
Vol 18 ◽  
pp. S312-S313
Author(s):  
X. Maldonado ◽  
I. Azinovich ◽  
V. Macías ◽  
J. Martinez Cedrés ◽  
A. Zapatero ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation ◽  
Intermediate Risk ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document